Cigna Group (CI) Could Be 58% Undervalued On PBM And Claims Review Concerns

Cigna Group (CI) continues to draw attention after recent share performance, with the price closing at US$270.53. Recent returns over the past month and the past 3 months have trended lower, sharpening focus on its fundamentals.

For context, Cigna Group’s 1-day share price return of 0.96% comes after the stock slipped 4.35% over 30 days and 5.99% over 90 days. The 1-year total shareholder return is down 11.04% despite a 44.70% gain over five years, which points to fading short term momentum against a still positive long run record.

Compare Cigna Group’s recent pullback with hand picked peers by scanning the 31 resilient stocks with low risk scores, which have held up better through recent market swings.

For Cigna Group, this slide could signal investors cooling on the story rather than a sharp change in how the business is actually performing. Which picture does the current valuation paint?

Most Popular Narrative: 58% Undervalued

On the most followed valuation view, Cigna Group’s fair value of $636.28 sits far above the recent $270.53 close. This puts the current slide against a backdrop of a very large quoted discount.

Cigna offers a 55.3% raw discount because the market is not valuing growing earnings in isolation. It is pricing political hostility toward PBMs, restrictions on Express Scripts, uncertainty around automated claims review, declining customer counts, uneven cash conversion, and the possibility that today’s most profitable practices may not remain tomorrow’s permissible ones.

See why 4 investors see Cigna Group as 57% undervalued.

Result: Fair Value of $636.28 (UNDERVALUED)

Still, the Cigna Group story could shift quickly if regulatory pressure on pharmacy benefit practices tightens further or if operating cash flow continues to lag reported earnings power.

Find out about the key risks to this Cigna Group narrative.

Next Steps

Mixed signals around Cigna Group can pull you in both directions, so move quickly and test the story against the data that matters to you, then weigh the 6 key rewards and 1 important warning sign.

Looking for more Cigna Group investment ideas?

If Cigna Group has sharpened your focus on pricing and risk, do not stop here. Use Simply Wall Street's screener to surface fresh, data driven ideas that match your checklist.

• Target potential value opportunities by scanning companies with strong fundamentals using the 31 high quality undervalued stocks.
• Strengthen your income toolkit by reviewing businesses with higher yields through the 7 dividend fortresses.
• Reduce blind spots around financial resilience by checking the list of solid balance sheet and fundamentals (26 results) before capital moves elsewhere.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com